Torrent Pharma net profit rises 2.8 percent to Rs 330 crore in Q1
New Delhi: Drug firm Torrent Pharmaceuticals on Tuesday reported a 2.8 percent rise in its consolidated net profit to Rs 330 crore for the quarter ended in June.
The company had posted a net profit of Rs 321 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a regulatory filing.
Consolidated revenue from operations of the company stood at Rs 2,134 crore for the quarter under consideration. It was Rs 2,056 crore for the same period a year ago, it added.
India revenues at Rs 1,093 crore, grew by 18 percent for the quarter ended June 30, 2021, Torrent Pharma said.
Regarding COVID drugs, Torrent has launched baricitinib during the quarter and is currently conducting clinical trials for molnupiravir; more partnerships are under evaluation to widen covid portfolio, it added.
Read also: MSD in talks with 5 Indian drugmakers for clinical trial of COVID drug Molnupiravir
US revenues at Rs 266 crore, were down by 29 percent. Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities, Torrent Pharma said.
Revenue for Brazil for the quarter under consideration was at Rs 153 crore, up by 9 percent and Germany revenues were at Rs 260 crore, up by 5 percent, the filing said.
Read also: Revise phase 3 clinical trial protocol for Tapentadol Nasal Spray: CDSCO panel tells Torrent Pharma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.